Search for: "AMGEN INC." Results 461 - 480 of 704
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
1 Jul 2010, 1:32 pm by Richard Renner
Grassley letters are available in the continuation of this blog entryBelow are links to the letters sent by Grassley to: Abbott Laboratories Amgen AstraZeneca Pharmaceuticals Boehringer Bristol-Myers Squibb Company Eisai Corporation of America Eli Lilly and Company Forest Laboratories GlaxoSmithKline Hoffman-La Roche Inc. [read post]
5 Feb 2008, 11:03 am
Heintz of Porter Wright Morris & Arthur in the firm's Nanotechnology Law Report Podcast of Maniloff's top ten insurance coverage cases of 2007 - Portland attorney David Rossmiller of Dunn Carney in the firm's Insurance Coverage Law Blog Implications of the Amgen-Takeda deal - Management consultant Cliff Mintz of BioInsights Inc. in his Bio Job Blog [read post]
16 Aug 2012, 2:00 am by Kara OBrien
Ct. 1414 (2012)–relating to the statute of limitations under Section 16 of the Securities and Exchange Act of 1934, and granted review in two other cases–Amgen, Inc. v. [read post]
15 Jul 2021, 2:54 pm by Kevin LaCroix
In its June 21, 2021 decision in Goldman Sachs Group, Inc. v. [read post]
5 Sep 2016, 6:46 pm by Dennis Crouch
Amgen Inc., et al., No. 15-1039 (Does the notice requirement of the BPCIA create an effective six-month exclusivity post-FDA approval?) [read post]